KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Tax Provisions (2021 - 2026)

AbCellera Biologics filings provide 6 years of Tax Provisions readings, the most recent being -$6.4 million for Q1 2026.

  • Quarterly Tax Provisions rose 13.46% to -$6.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$30.2 million through Mar 2026, up 29.4% year-over-year, with the annual reading at -$31.2 million for FY2025, 16.93% up from the prior year.
  • Tax Provisions hit -$6.4 million in Q1 2026 for AbCellera Biologics, up from -$10.6 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $62.2 million in Q1 2022 and bottomed at -$12.6 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$1.3 million, with a median of -$7.4 million recorded in 2025.
  • The largest annual shift saw Tax Provisions surged 655.76% in 2022 before it plummeted 7301.98% in 2023.
  • AbCellera Biologics' Tax Provisions stood at -$1.5 million in 2022, then grew by 4.41% to -$1.5 million in 2023, then tumbled by 769.08% to -$12.6 million in 2024, then grew by 16.36% to -$10.6 million in 2025, then skyrocketed by 39.62% to -$6.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Tax Provisions are -$6.4 million (Q1 2026), -$10.6 million (Q4 2025), and -$11.6 million (Q3 2025).